LeoSat’s Commercial Traction Accelerates to Hit US$2Billion Milestone
LeoSat Enterprises today announced it has signed more than US$2Billion in commercial agreements ahead of launching the world’s fastest, most secure and widest coverage data network delivered over a constellation of low-Earth-orbit satellites. These pre-launch agreements signal strong demand for LeoSat’s business backbone in space across a wide range of fast-growing data and mobility sectors including, Enterprise, Telecoms, Government, Maritime, Healthcare and Finance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005277/en/
LeoSat's Commercial Traction Accelerates to Hit US$2Billion Milestone (Photo: Business Wire)
With data volumes exploding, the increasing demand to move large quantities of data quickly and securely around the world is fast outpacing the infrastructure needed to carry it. LeoSat has developed a unique system architecture – a space-based MPLS network - providing Gigabits of secure connectivity with lower latencies than fiber, opening-up new possibilities for companies looking for scalable, flexible solutions for their expanding networks.
“Whilst the list of companies launching “build it and they will come” mega satellite constellations continues to grow, we believe that our commercial agreements valued at over US$2Billion clearly demonstrate LeoSat’s unique solution is more than a vision. LeoSat is solving an essential business need that not only resonates with our customers but has also attracted the firm backing of two leading satellite companies - SKY Perfect JSAT and Hispasat”, said Mark Rigolle, CEO of LeoSat Enterprises.
Our most recent customer agreements include X2nSat, which has selected LeoSat’s laser-enabled data network to support the ever-expanding needs of the healthcare industry, and FMC GlobalSat, which provides seamless onshore and offshore network access that will enable enormous productivity and efficiency improvements over legacy satellite infrastructures.
LeoSat was recently granted a license by the FCC to operate its network in the U.S., and also announced last year the first details in the development of its ground system through an agreement with Phasor Solutions, the developer of leading, enterprise-grade electronically-steered antenna (ESA) systems.
Mark Rigolle, added: “LeoSat has quickly changed the perception that satellite is a last resort for data communications by pairing the speed of fiber with the ubiquity of satellite and a whole new level of ultra-security. We are enabling a paradigm shift by expanding the existing satellite services market, opening- up new markets for space-based data networking for enterprise, telecoms and government communications across the globe. From healthcare, maritime, energy, banking and remote connectivity, we are continually being engaged by new sectors, and the current momentum in our pre-launch sales clearly demonstrates that LeoSat is the solution of choice for business connectivity. Clearly LeoSat has struck a chord with a data network built for business, as it took just over 2 years for us to hit US$ 1 Billion in customer commitments and under 12 months to double that figure at US$2 Billion”.
NOTE TO EDITORS
To find out more about LeoSat, come along to one of the panels at the #SATShow in Washington DC.
- Monday 6 May, 1.30pm: An Introduction to HTS and Other Acronyms (Unveiled Theater)
- Wednesday 8 May, 3pm: Integrating LEO Constellations Into Teleport Services (Room 147)
- Thursday 9 May, 10:45am: Executive Round Table – LEO/MEO Systems (Room 146)
To arrange an interview, please contact Melanie Dickie. Email: Melanie@leosat.com or call +31 6 14 22 97 62
About LeoSat Enterprises
LeoSat Enterprises was established to leverage the latest developments in satellite communications technologies to develop and launch a new low-earth-orbit satellite constellation which will provide the first commercially available, business grade, extremely high-speed and secure data service worldwide.
With up to 108 low-earth-orbit communications satellites in the constellation LeoSat is the first company to have all the High Throughput Satellites (HTS) in the constellation interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones and without the need for any terrestrial touchpoints. This unique set of features enables LeoSat to provide instant infrastructure from anywhere to everywhere which is fast, secure and reliable.
Based in Washington DC, LeoSat is currently working with Thales Alenia Space for the low-earth-orbit constellation of Ka-band communications satellites. Once operational, the constellation will provide high-speed, low-latency and highly secure communications and bandwidth for business operations in the telecom backhaul, Energy, Maritime, Government and international business markets. Launch of the constellation is expected in 2020. www.leosat.com
VP Marketing & Communications, LeoSat Enterprises
Tel: +31 6 14 22 97 62
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CEST | Press release
SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti
Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CEST | Press release
In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CEST | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp
Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family11.10.2019 02:00:00 CEST | Press release
Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/ Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation) This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability. Development Background Advanced proces
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis10.10.2019 22:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005875/en/ “We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “These data suggest that filgotinib if approved, may play an important role in helping people living with rheumatoid arthritis achieve sustained, clinically meaningful responses.” “The
Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 201910.10.2019 20:05:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, October 26, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the con